Benefits
Migraine: traditional use, mixed trial evidence
Feverfew has a long traditional use for headache. In one RCT, a standardized CO2 extract (MIG-99) reduced migraine frequency versus placebo, but a Cochrane review of six trials found insufficient, low-quality evidence to confirm an effect overall, with only some preparations showing benefit. The inconsistency is largely attributed to variable parthenolide content across commercial products. Standardized parthenolide extracts (MIG-99) show more consistent results than unstandardized products.
Anti-inflammatory activity
Parthenolide inhibits NF-κB by covalently modifying the IκB kinase β subunit — a strong, irreversible anti-inflammatory mechanism also being investigated for cancer applications. This NF-κB inhibition reduces prostaglandin production, inflammatory cytokines, and may contribute to the anti-migraine effects through reduced neuroinflammation.
Platelet aggregation inhibition
Parthenolide inhibits platelet aggregation and reduces serotonin release from platelets — two mechanisms historically proposed to explain feverfew's anti-migraine effects, as platelet serotonin release is elevated before migraines and contributes to vasomotor changes initiating the migraine cascade.
Mechanism of action
Parthenolide NF-κB covalent inhibition
Parthenolide contains an alpha-methylene-gamma-lactone moiety that covalently alkylates cysteine 179 of IKKβ — irreversibly inhibiting IκB kinase and NF-κB activation. This strong, sustained NF-κB blockade reduces expression of inflammatory genes including COX-2, TNF-α, and IL-6 in neuronal and immune cells.
Serotonin release inhibition from platelets
Parthenolide inhibits serotonin secretion from platelets by blocking secretory arachidonate metabolism and prostaglandin-thromboxane synthesis. Since platelet serotonin release before migraines contributes to vasomotor dysregulation, this mechanism was the original rationale for feverfew in migraine prevention.
Neutrophil degranulation inhibition
Feverfew extracts inhibit neutrophil degranulation and chemotaxis — reducing the release of inflammatory proteases and reactive oxygen species that contribute to neurogenic inflammation in migraine and inflammatory conditions.
Clinical trials
Randomized, double-blind, placebo-controlled trial of MIG-99 feverfew CO2 extract (6.25 mg three times daily, equivalent to ~5-10 mg parthenolide-content product per day) vs placebo in 170 migraine patients for 16 weeks. Outcomes: monthly migraine frequency, severity, MIDAS scores. (Diener et al. 2005, Cephalalgia)
170 migraine patients. 16-week intervention.
MIG-99 reduced migraine frequency by ~24% in subgroup with ≥4 migraines at baseline. Migraine duration and severity also reduced. Note: Cochrane review (Wider et al. 2015, n=561) concluded there was insufficient, low-quality evidence to confirm feverfew is more effective than placebo, with mixed results and variable trial quality. The AAN/AHS 2012 migraine prevention guideline gave feverfew Level B (probably effective) — though enthusiasm has tempered. Standardized extracts (MIG-99) more reliable than crude herbs. 4-12 weeks needed for effect.